Track Brainstorm Cell Therapeutics's minority interest ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), BCLI shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BCLI's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Brainstorm Cell Therapeutics is outperforming or lagging.
Tracking BCLI's minority interest over time shows whether Brainstorm Cell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this minority interest page, Stockcircle has Brainstorm Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.
Brainstorm Cell Therapeutics's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.